The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
Primary Purpose
Renal Impairment
Status
Completed
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
LEO 27847
Sponsored by
About this trial
This is an interventional treatment trial for Renal Impairment
Eligibility Criteria
Main Inclusion Criteria:
- Male and/or non-childbearing potential female, 18 years of age and older, healthy or with stable renal impairment (deemed stable by the referring physician for at least the last 4 weeks and not expected to change significantly during the next 3 months)
- BMI ≥18.0 and ≤ 42 kg/m2
- Patients with stable concomitant medical conditions
Healthy subjects or patients with a creatinine clearance (at the time of screening) estimated using the formula of Cockcroft and Gault within the range of:
- ≥ 50 to ≤ 80 mL/min (Mild Group: 8 subjects),
- ≥ 30 to < 50 mL/min (Moderate Group: 8 subjects),
- < 30 mL/min (Severe Group: 8 subjects).
Main Exclusion Criteria:
- Patients with renal transplants or currently on haemodialysis or peritoneal dialysis
- Clinically significant illness or surgery within 4 weeks prior to dosing
- Clinically significant ECG abnormalities or vital sign abnormalities at screening
- History of stroke, cerebrovascular disorder, coronary angioplasty and coronary bypass graft
- Clinically significant history or presence of any gastrointestinal pathology
Use of medications other than their stable medications within 14 days prior to administration of investigational product or over-the-counter products within 7 days prior to administration of investigational product, except for:
- multivitamins or vitamin D taken on a regular basis
- topical products without systemic absorption
- Hemoglobin ≤ 90 g/L
- Serum total calcium (adjusted for albumin) level < 2.25 mmol/L
- Clinically significant history of congestive heart failure, cardiac dysfunction or liver disease
Sites / Locations
- Anapharm
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
LEO 27847
Arm Description
Outcomes
Primary Outcome Measures
PK parameters
(AUC, Cmax)in each group of renal impairment
Secondary Outcome Measures
PD parameters
(Calcium, phosphate, PTH), Vitamin D in each group of renal impairment
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01141179
Brief Title
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
Official Title
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
May 2010 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
February 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LEO Pharma
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study will investigate the impact of reduced renal function on the pharmacokinetic and pharmacodynamic profile of LEO 27847. Volunteers with different degrees of renal impairment will be administered one dose of the investigational drug and then followed until investigational drug is eliminated from the body.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Impairment
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LEO 27847
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
LEO 27847
Intervention Description
2 mL (0.1 mg) dose of oral solution
Primary Outcome Measure Information:
Title
PK parameters
Description
(AUC, Cmax)in each group of renal impairment
Time Frame
1 week
Secondary Outcome Measure Information:
Title
PD parameters
Description
(Calcium, phosphate, PTH), Vitamin D in each group of renal impairment
Time Frame
1 week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Main Inclusion Criteria:
Male and/or non-childbearing potential female, 18 years of age and older, healthy or with stable renal impairment (deemed stable by the referring physician for at least the last 4 weeks and not expected to change significantly during the next 3 months)
BMI ≥18.0 and ≤ 42 kg/m2
Patients with stable concomitant medical conditions
Healthy subjects or patients with a creatinine clearance (at the time of screening) estimated using the formula of Cockcroft and Gault within the range of:
≥ 50 to ≤ 80 mL/min (Mild Group: 8 subjects),
≥ 30 to < 50 mL/min (Moderate Group: 8 subjects),
< 30 mL/min (Severe Group: 8 subjects).
Main Exclusion Criteria:
Patients with renal transplants or currently on haemodialysis or peritoneal dialysis
Clinically significant illness or surgery within 4 weeks prior to dosing
Clinically significant ECG abnormalities or vital sign abnormalities at screening
History of stroke, cerebrovascular disorder, coronary angioplasty and coronary bypass graft
Clinically significant history or presence of any gastrointestinal pathology
Use of medications other than their stable medications within 14 days prior to administration of investigational product or over-the-counter products within 7 days prior to administration of investigational product, except for:
multivitamins or vitamin D taken on a regular basis
topical products without systemic absorption
Hemoglobin ≤ 90 g/L
Serum total calcium (adjusted for albumin) level < 2.25 mmol/L
Clinically significant history of congestive heart failure, cardiac dysfunction or liver disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Larouche, MD
Organizational Affiliation
Anapharm
Official's Role
Principal Investigator
Facility Information:
Facility Name
Anapharm
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M2P 1N6
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
We'll reach out to this number within 24 hrs